Just went over to slime pit. Could only stand to read the
Just went over to slime pit. Could only stand to read the last 50 posts, but it seems that the bashers are out in full force with completely bogus claims.
In case someone here read some of that garbage, let me say:
Readers' Digest version: they are a bunch of liars who are panicking and trying to talk the stock price down.
More detailed response:
1) no one there has any inside information
2) There is NO reason to expect Prurisol results on Friday or Monday. The company never promised such a thing.
3) There is no truth to the claim that Prurisol has failed and somehow the bashers magically know about it
4) Prurisol has far fewer side effects (nothing serious) than Otezla and the other biologics. Therefore, even if Prurisol were to prove less effective (for which there is absolutely NO evidence), it is likely that good doctors would try their patients on Prurisol first, then the more dangerous drugs if P failed to work. But again:
There is NO reason to assume that Prurisol is less effective than existing drugs, given the results of the clinical trial to date
5) Tremendous misinformation is being posted there. One poster in particular seems to confuse Brilacidin and Prurisol. Don't believe anything negative you read there. They have no more information than anyone else, and they are posting lies to scare the naive newbie investors away.
6) AND MOST IMPORTANTLY: they are claiming that the future of the company rests on the success of Prurisol. NONSENSE ! ! ! ! Prurisol is certainly not priced into the share price of IPIX. IPIX should be trading at least twice as high, just on the basis of the Brilacidin-UP clinical trial, much less the Bril-OM and Kevetrin trials that are in the pipeline. If Prurisol works great, then swell, that means we can look for a partner and get a whole bunch of cash. If results are inconclusive (which I do not expect, based on the previous results), then the company is still grossly undervalued.
5
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...
Continue Reading
Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...
Continue Reading
KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...
Continue Reading
Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....
Continue Reading
Jackson's Next Manufacturing Frontier Well, the folks down in Jackson, Michigan, are prepping to cut the red ribbon on something that's got me leaning forward in my seat. The Advanced Manufacturing Training Center (AMTC) is pulling out all the stops with their new ManuTech Prototyping Center. Yup, this center is about to become the playground for startups, manufacturers,...
Continue Reading
Unexpected Delay for IEHP's Community Hub Straight outta Rancho Cucamonga, we've got some news that'll have folks in San Bernardino holding their breath a little longer. The Inland Empire Health Plan (or IEHP if you're part of the 1.4 million served by them) had folks pumped for their new Community Wellness Center. But guess what? They had to slam the brakes on the grand...
Continue Reading
An Investor's Glance at Dana's Strategic Moves Dana Incorporated (NYSE: DAN) just pulled a bold move with their tender offers, snapping up a hefty $357,873,000 in outstanding principal on their senior notes. This isn’t just pocket change; folks holding out for securities can feel the tension of watching big numbers get shuffled around. You gotta wonder, what's the play...
Continue Reading
A Milestone for Mentorship at Greenberg Traurig In the often cutthroat jungle of law, finding someone who actually gives a damn about you is as rare as finding a unicorn. Yet, there it is—Brad Kaufman, at the helm of Greenberg Traurig's professional development, proving that mentorship can be more than just a checkbox on a quarterly review. Award for Exceptional...
Continue Reading
HiTHIUM and Cambridge's New Energy Venture There's a big splash coming out of Xiamen, folks. HiTHIUM, a heavyweight in the energy storage sector, has decided to team up with the University of Cambridge. They inked a deal aiming to bridge the academic ivory tower with industrial grit, focusing on long-duration energy storage. It was all sealed during the Global Energy...
Continue Reading
MV Throws Support Behind Aesch for FTA Role In this wild world where public transit feels the heat from financial burdens, MV Transportation's recent move to support Mark Aesch for the Federal Transit Administration's top spot isn’t just a nod of approval—it's a full-blown trumpet blast. They're not just doling out a basic endorsement here; they're practically waving...
Continue Reading
Top 5 Most Recently Viewed Articles
Understand the Semtech Corporation Class Action Lawsuit Investors in Semtech Corporation, a well-known player in the semiconductor industry, are now being notified of a class action lawsuit. This legal matter aims to seek justice for those adversely affected by alleged securities fraud. The law firm Levi & Korsinsky, LLP is leading this initiative, reaching out to...
Continue Reading
Celebrating a Music Education Legend In an exciting development for music education, Gary P. Gilroy, a distinguished Professor of Music Emeritus and Director of Bands Emeritus at California State University, Fresno, has been recognized for his outstanding contributions in this field. He was recently awarded the prestigious George N. Parks Award for Leadership in Music...
Continue Reading
Embracing AI Transparency in the Workplace As technology continues to progress rapidly, it's crucial for leaders to prioritize clear communication about how artificial intelligence is affecting the job market. Recently, Jim Kavanaugh, the CEO of World Wide Technology, highlighted that employees are smart enough to see through any misleading narratives surrounding AI's...
Continue Reading
Innocan Pharma's Expansion in Asian Markets Innocan Pharma Corporation, a key player in the pharmaceutical and biotechnology arenas, has taken significant strides in its efforts to expand its intellectual property coverage for its innovative liposomal CBD injection. This strategic development focuses on the expansive Asian pharmaceutical market, particularly highlighting...
Continue Reading
CYFOX Introduces Groundbreaking Email Security Solution CYFOX, a forward-thinking cybersecurity company, has recently launched an advanced email security solution that integrates seamlessly with Microsoft 365. This innovative framework eliminates the hassle of MX record adjustments and domain-level alterations, making it easier for organizations to enhance their email...
Continue Reading